Any prior cancer history (any site, treatment completed, currently no evidence of active...

Детермінований перегляд YAML-сутності з джерельної бази. Клінічний авторитет лишається за вказаними source ID та статусом клінічного sign-off.

ID	`RF-UNIVERSAL-PRIOR-CANCER-SECONDARY-RISK`
Тип	Тривожна ознака
Статус	переглянуто 2026-05-18 \| очікує клінічного підпису
Хвороби	Не вказано
Джерела	`SRC-COG` `SRC-NCCN-BREAST-2025` `SRC-NCCN-COLON-2025`

Походження тривожної ознаки

Визначення	Any prior cancer history (any site, treatment completed, currently no evidence of active recurrent disease — survivor cohort). Secondary-malignancy risk in cancer survivors is well-characterized in two cohorts: (1) Childhood Cancer Survivor Study (CCSS) + Children's Oncology Group Long-Term Follow-Up (COG-LTFU) Guidelines v5.0 — survivors of pediatric cancers face cumulative incidence of second neoplasm reaching 20-25% at 30 years post- diagnosis, dominated by therapy-related solid tumors (breast in chest-RT survivors, CNS in cranial-RT, thyroid in neck-RT, sarcoma and gastrointestinal in TBI / alkylator survivors) and therapy-related myeloid neoplasms; (2) NCCN Survivorship 2025 guidelines for adult-cancer survivors — second-primary-cancer risk is elevated 1.5-3× general-population baseline depending on treatment exposures (anthracycline + chest-RT for Hodgkin and breast survivors carr...
Клінічний напрям	investigate
Категорія	other

Логіка спрацьовування

{
  "any_of": [
    {
      "finding": "prior_cancer_history_completed",
      "value": true
    }
  ],
  "type": "composite_score"
}

Нотатки

Pre-triage universal RedFlag — any prior-cancer survivor with treatment completed. Authoring intent: route to structured survivorship surveillance (NCCN Survivorship 2025 + COG-LTFU v5.0 treatment-summary-driven cadence). risk_category=iatrogenic reflects that the elevated secondary-malignancy risk is therapy-related rather than tumor-biology-intrinsic. With relevant_diseases=["*"], engine does NOT attach Indication tracks via prevention path (plan.py:297 excludes "*") — universal Indications anchored to DIS-CRC (heterogeneous survivor surveillance defaults to CRC + breast cadence individualization) are documentation / sidecar candidates pending future engine extension. STUB pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode.

Де використовується

Indications

IND-UNIVERSAL-PRIOR-CANCER-PREVENTION-ROUTINE-FOLLOWUP - IND-UNIVERSAL-PRIOR-CANCER-PREVENTION-ROUTINE-FOLLOWUP
IND-UNIVERSAL-PRIOR-CANCER-PREVENTION-SURVIVORSHIP-PROGRAM - IND-UNIVERSAL-PRIOR-CANCER-PREVENTION-SURVIVORSHIP-PROGRAM